Key Highlights
- Third-quarter 2026 collaboration Revenue was USD 3.0 million, against USD 10.8 million.
- Net loss was USD 20.3 million, or USD 0.93 per share.
- Cash, cash equivalents and marketable securities were USD 314.3 million at September 30, 2026.
- Gilead paid a first USD 75.0 million extension fee in November 2026.
Assembly Biosciences (NASDAQ:ASMB) reported third-quarter 2026 collaboration revenue of USD 3.0 million, against an estimate of USD 9.07 million, and a net loss of USD 0.93 per share, against an estimate of a loss of USD 0.66. The biotechnology company develops small-molecule therapeutics for serious viral and liver diseases, and all of its revenue in the period came from a related party, Gilead Sciences.
Quarterly Results
Collaboration revenue from a related party was USD 3.0 million for the three months ended September 30, 2026, against USD 10.8 million a year earlier. For the nine months, it was USD 24.5 million, against USD 29.8 million. The filing states the company recognized USD 11.3 million as a reduction of collaboration revenue during the three and nine months ended September 30, 2026, and that it updates its estimate of variable consideration at each reporting period.
Research and development expenses were USD 20.2 million, against USD 16.6 million, and general and administrative expenses were USD 6.1 million, against USD 5.1 million. Total operating expenses were USD 26.4 million, against USD 21.7 million, and the loss from operations was USD 23.4 million, against USD 10.9 million.
Interest and other income, net, was USD 3.2 million, against USD 1.7 million. Net loss was USD 20.3 million, against USD 9.2 million, and net loss per share was USD 0.93, against USD 0.72. For the nine months, net loss was USD 33.2 million, or USD 1.73 per share, against USD 28.2 million, or USD 3.03 per share. The filing states that adjustments decreased the net loss for the nine months by USD 6.7 million, lowering basic and diluted net loss per share by USD 0.35.
Gilead Collaboration and Pipeline
The filing describes two long-acting helicase-primase inhibitors for recurrent genital herpes, GS-1179 and GS-5366, which are exclusively licensed to Gilead. It states Gilead made a USD 35.0 million payment on exercising its option for the helicase-primase inhibitor program, reflecting a USD 45.0 million opt-in fee net of USD 10.0 million in accelerated funding received in December 2024. Gilead has the sole right and responsibility for further clinical development and commercialization, and the company elected in September 2026 to participate in the profit-share for the program.
Other programs listed include ABI-6250, an orally bioavailable NTCP inhibitor for chronic hepatitis Delta virus infection and for primary biliary cholangitis and primary sclerosing cholangitis, and ABI-4334, a capsid assembly modulator for hepatitis B virus that the company does not plan to advance further without a partner. Its pipeline also includes ABI-7272, an oral broad-spectrum non-nucleoside polymerase inhibitor for transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing.
The company states it has not derived any revenue from product sales and has no approved products.
Cash and Financing
As of September 30, 2026, the company held cash, cash equivalents and marketable securities of USD 314.3 million. It received the first USD 75.0 million extension fee from Gilead under the Option, License and Collaboration Agreement in November 2026. Total Assets were USD 325.3 million, against USD 257.6 million at December 31, 2025, and total stockholders' Equity was USD 298.8 million, against USD 206.8 million. The accumulated Deficit was USD 865.2 million.
The weighted average number of common shares outstanding was 21,780,874 for the quarter, against 12,686,122 a year earlier. During the quarter, the company issued 510,205 shares of common stock on the exercise of warrants, with net proceeds of approximately USD 10.3 million. In August 2025, the company sold 5,591,840 shares of common stock and pre-funded warrants to purchase up to 1,040,820 shares, together with Class A and Class B warrants, in an underwritten offering.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...